Q3 EPS Estimate for Neurocrine Biosciences Cut by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report released on Monday, February 17th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $1.28 for the quarter, down from their previous estimate of $1.29. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ Q4 2025 earnings at $1.27 EPS and FY2026 earnings at $6.50 EPS.

Several other research firms have also issued reports on NBIX. Barclays increased their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Bank of America lowered their target price on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. HC Wainwright lowered their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Guggenheim lowered their target price on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a “hold” rating and a $138.00 target price on the stock. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Stock Up 0.3 %

NBIX stock opened at $114.26 on Wednesday. The company’s 50-day simple moving average is $136.97 and its 200-day simple moving average is $129.81. Neurocrine Biosciences has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $11.39 billion, a P/E ratio of 34.73, a PEG ratio of 0.78 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Insider Transactions at Neurocrine Biosciences

In other news, CFO Matt Abernethy sold 1,283 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $196,132.21. Following the completion of the sale, the chief financial officer now owns 32,681 shares in the company, valued at $4,995,944.47. This trade represents a 3.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 236,600 shares of company stock worth $34,348,261 in the last 90 days. Insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Toronto Dominion Bank increased its holdings in Neurocrine Biosciences by 3.9% in the 4th quarter. Toronto Dominion Bank now owns 13,183 shares of the company’s stock valued at $1,799,000 after purchasing an additional 499 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $290,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Neurocrine Biosciences by 19.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company’s stock valued at $146,068,000 after purchasing an additional 175,879 shares during the last quarter. Worldquant Millennium Advisors LLC increased its holdings in Neurocrine Biosciences by 44.1% in the 4th quarter. Worldquant Millennium Advisors LLC now owns 154,852 shares of the company’s stock valued at $21,137,000 after purchasing an additional 47,370 shares during the last quarter. Finally, Triglav Skladi D.O.O. acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $1,502,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.